<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4784">
  <stage>Registered</stage>
  <submitdate>16/07/2014</submitdate>
  <approvaldate>16/07/2014</approvaldate>
  <nctid>NCT02200770</nctid>
  <trial_identification>
    <studytitle>A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders</studytitle>
    <scientifictitle>A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2014-000253-36</secondaryid>
    <secondaryid>CD-IA-MEDI-551-1155</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - MEDI-551
Other interventions - Placebo

Experimental: MEDI551 - 

Placebo Comparator: Placebo - 


Other interventions: MEDI-551


Other interventions: Placebo
Matching placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to onset of an adjudicated NMO/NMOSD attack - time (days) to onset of an Adjudication Committee (AC) - determined NMO/NMOSD attack</outcome>
      <timepoint>From Day 1 of the study until on or before Day 197 of the randomized-controlled period.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Attack Rate - Annualized attack rate (total number of adjudicated NMO/NMOSD attacks normalized by person-years) during the duration of the Open-label Period</outcome>
      <timepoint>Annualized attack rate normalized by person/years during the open-label period, for a minimum of 1 year after the last subject enters and a maximum of 3 years after the last subject enters</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants with Adverse Events as a Measure of Safety and Tolerability - Treatment-emergent adverse events, treatment-emergent serious adverse events (TESAEs), including laboratory measurements as well as their changes or shift from baseline over time</outcome>
      <timepoint>From the start of treatment with investigational product until the end of the Safety Follow-up Period, for a total of 12 months following the last dose of investigational product</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>TMAX and CMAX - mean MEDI-551 concentration versus time data will be plotted by AQP4-IgG seropositive and seronegative subjects</outcome>
      <timepoint>From Day 1 of the study until on or before Day 197 of the randomized-controlled period.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of Anti-Drug Antibodies (ADAs) Directed Against MEDI-551 - Incidence of anti-drug antibodies (ADAs) directed against MEDI-551 (both predose and postdose for each subject)</outcome>
      <timepoint>From the start of treatment with investigational product until the end of the Safety Follow-up Period, for a total of 12 months following the last dose of investigational product</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Worsening in EDSS - Worsening from baseline in EDSS at last visit during the RCP</outcome>
      <timepoint>From the start of treatment with invesigational product up to Day 197 of Randomised Control Period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Low-Contrast Visual Acuity Binocular Score - Change from baseline in low-contrast visual acuity binocular score measured by low-contrast Landolt C Broken Rings Chart</outcome>
      <timepoint>From the start of treatment with invesigational product up to Day 197 of Randomised Control Period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative Total Active MRI Lesions - Cumulative total active MRI lesions (new Gd-enhancing or new/enlarging T2)</outcome>
      <timepoint>From the start of treatment with invesigational product up to Day 197 of Randomised Control Period</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of NMO/NMOSD-Related In-Patient Hospitalizations - Number of NMO/NMOSD-related in-patient hospitalizations</outcome>
      <timepoint>From the start of treatment with invesigational product up to Day 197 of Randomised Control Period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Men and women 18 years or older with diagnosis of NMO/NMOSD

          2. Confirmation of NMO/NMOSD status:

               1. AQP4-IgG sero-positive NMO/NMOSD with at least one attack requiring rescue
                  therapy in the last year or two attacks requiring rescue therapy in the last 2
                  years

               2. AQP4-IgG sero-negative NMO with at least one attack requiring rescue therapy in
                  the last year or two attacks requiring rescue therapy in the last 2 years

          3. Able and willing to give written informed consent and comply with the requirements of
             the study protocol.

          4. EDSS &lt;= 7.5 (8 in special circumstances)

          5. Men and women of reproductive potential must agree to use a highly effective method of
             birth control from screening to 6 months after final dose of the investigational
             product.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Lactating and pregnant females

          2. Treatment with any investigational agent within 4 weeks of screening

          3. Known history of a severe allergy or reaction to any component of the investigational
             product formulation or history of anaphylaxis following any biologic therapy.

          4. Known active severe bacterial, viral, or other infection or any major episode of
             infection requiring hospitalization.

          5. History of alcohol, drug, or chemical abuse, or a recent history of such abuse &lt; 1
             year prior to randomization

          6. Receipt of the following at any time prior to randomization:

               1. Alemtuzumab

               2. Total lymphoid irradiation

               3. Bone marrow transplant

               4. T-cell vaccination therapy

          7. Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior
             screening and B-cells below the lower limit of normal.

          8. Receipt of IVIG within 1 month prior to randomization.

          9. Receipt of any of the following within 3 months prior to randomization:

               1. Natalizumab (TysabriÂ®)b.

               2. Cyclosporin

               3. Methotrexate

               4. Mitoxantrone

               5. Cyclophosphamide

               6. Tocilizumab

               7. Eculizumab

         10. History of Hepatitis B and/or Hepatitis C (Hep B/C at screening)

         11. Known history of a primary immunodeficiency (congenital or acquired) or an underlying
             condition such as human immunodeficiency virus (HIV) infection

         12. History of malignancies, apart from squamous cell or basal cell carcinoma of the skin
             treated with documented success of curative therapy &gt; 3 months prior to randomization

         13. Any concomitant disease other than NMO/NMOSD that required treatment with oral or
             intravenous steroids at doses over 20 mg a day for over 21 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>6/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>252</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>10/05/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Melbourne</hospital>
    <postcode>3065 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Barranquilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cali</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Teplice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tallinn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tartu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>DÃ¼sseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Marburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rostock</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tuebingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Thessaloniki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Kowloon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Shatin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Esztergom</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Nyiregyhaza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ramat Gan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aomori-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Bunkyo-ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ota-ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Sendai-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shinjuku-ku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tsukuba-shi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Ube</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Goyang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Jongno-gu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Ciudad De Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Monterrey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>San Luis Potosi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Moldova, Republic of</country>
      <state>Chisinau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Bellavista</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Katowice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>LÃ³dz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Olsztyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Amadora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Braga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Belgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Khabarovsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Krasnoyarsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Nizhniy Novgorod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Novosibirsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Omsk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Ufa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Belgrade</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Nis</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia</country>
      <state>Uzice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Hualien City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Muang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Samsun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Dnipropetrovsk</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MedImmune LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD
      attack in subjects with NMO/NMOSD.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02200770</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>AstraZeneca Clinical Study Information Center</name>
      <address />
      <phone>1-877-240-9479</phone>
      <fax />
      <email>information.center@astrazeneca.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>